International Psoriasis Council

Advancing Knowledge. Improving Care.

Yu

Sawada

,

MD

Psoriasis Care Director
Department of Dermatology, University of Occupational and Environmental Health
Kitakyushu
,
Japan
Councilor Since: September 8, 2023
IPC Councilor
Dr. Yu Sawada is a psoriasis researcher and dermatologist. He is the Psoriasis Care Director at the University of Occupational and Environmental Health in Kitakyushu, Fukuoka, Japan, with 14 years in patient care. Dr. Sawada has 17 papers on psoriasis-related topics, with publications about the epigenetic control of innate immune tolerance to investigate the impact of lifestyle on inflammatory skin diseases. Dr. Sawada’s work delves into various aspects of psoriasis, including its association with systemic inflammatory disorders, the detection of psoriatic arthritis, and the effects of different treatments on patients. Dr. Sawada has actively engaged in clinical trials, having conducted two notable studies. The first trial focused on the utility of the Psoriasis Epidemiology Screening Tool (PEST) questionnaire to identify psoriatic arthritis patients within the Japanese psoriasis population. The second study examined the presence of Mycobacterium tuberculosis infection in psoriatic patients undergoing biologics treatment, drawing data from 18 Japanese facilities. In addition to his research and clinical work, Dr. Sawada has actively participated in various scientific congresses and is affiliated with esteemed professional societies. He has presented his findings at annual events such as the Society for Investigative Dermatology (SID) meetings and the Japanese Society for Investigative Dermatology (JSID).
Last Updated:
10/24/2023

Areas of Interest

I have conducted a variety of basic and clinical investigations with an emphasis on the relationship between daily lifestyle variables and psoriasis, particularly the effect of omega-3 fatty acids on psoriasis, based on my experiences as an occupational physician. Additionally, one of the most intensive studies is to clarify the molecular mechanisms of psoriasis-mediated systemic inflammatory diseases to provide a better knowledge of the pathogenesis and treatment for psoriasis patients.

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026